The US regulator will provide verdicts on cancer projects from TG and Athenex, while Sarepta aims for its third Duchenne approval.
A rollercoaster year for biopharma ended with investors firmly deciding that the pandemic was an opportunity, not a threat.
As Curis clinically backs a novel oncology mechanism, several companies might review their own similarly acting projects.
Hot on the heels of a successful Ash meeting, TG Therapeutics shows that it might have a multiple sclerosis challenger to Ocrevus.
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
Unveiling of abstracts for December’s haematology meeting sent Crispr up and Allogene down, but the biggest beneficiary was private.
Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.
The Unity-CLL trial shows ublituximab plus umbralisib conferring an unexpected progression-free survival benefit.